Imagion Biosystems Limited
Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It is involved in the nanotechnology; biotechnology; and cancer diagnostics businesses. The company develops MagSense, which completed Phase 1 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, … Read more
Imagion Biosystems Limited (IBXXF) - Net Assets
Latest net assets as of June 2025: $-3.87 Million USD
Based on the latest financial reports, Imagion Biosystems Limited (IBXXF) has net assets worth $-3.87 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($932.48K) and total liabilities ($4.80 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.87 Million |
| % of Total Assets | -414.57% |
| Annual Growth Rate | N/A |
| 5-Year Change | -117.68% |
| 10-Year Change | N/A |
| Growth Volatility | 147.76 |
Imagion Biosystems Limited - Net Assets Trend (2014–2024)
This chart illustrates how Imagion Biosystems Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Imagion Biosystems Limited (2014–2024)
The table below shows the annual net assets of Imagion Biosystems Limited from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-2.28 Million | +39.73% |
| 2023-12-31 | $-3.79 Million | -180.98% |
| 2022-12-31 | $4.68 Million | -64.84% |
| 2021-12-31 | $13.31 Million | +3.03% |
| 2020-12-31 | $12.91 Million | +334.30% |
| 2019-12-31 | $2.97 Million | -23.15% |
| 2018-12-31 | $3.87 Million | -44.35% |
| 2017-12-31 | $6.95 Million | -40.52% |
| 2016-12-31 | $11.69 Million | +231.88% |
| 2015-12-31 | $-8.86 Million | -123.17% |
| 2014-12-31 | $-3.97 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Imagion Biosystems Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6296755700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $62.54 Million | % |
| Other Comprehensive Income | $2.19 Million | % |
| Total Equity | $-2.28 Million | 100.00% |
Imagion Biosystems Limited Competitors by Market Cap
The table below lists competitors of Imagion Biosystems Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PNC FINL SER
BE:PNP
|
$1.74 Million |
|
Oriental Trimex Limited
NSE:ORIENTALTL
|
$1.74 Million |
|
Tasman Resources Ltd
PINK:TASEF
|
$1.74 Million |
|
ELECTRONIC ARTS - Dusseldorf Stock Exchang
DU:ERT
|
$1.75 Million |
|
VERISK ANLYTCS-A
BE:VA7A
|
$1.74 Million |
|
Taoping Inc
NASDAQ:TAOP
|
$1.74 Million |
|
M&T BANK - Dusseldorf Stock Exchang
DU:MTZ
|
$1.74 Million |
|
Citra Nusa Holdings Bhd
KLSE:5104
|
$1.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Imagion Biosystems Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -3,788,047 to -2,282,980, a change of 1,505,067.
- Net loss of 2,066,957 reduced equity.
- New share issuances of 3,125,226 increased equity.
- Other comprehensive income decreased equity by 2,736,036.
- Other factors increased equity by 3,182,834.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.07 Million | -90.54% |
| Share Issuances | $3.13 Million | +136.89% |
| Other Comprehensive Income | $-2.74 Million | -119.84% |
| Other Changes | $3.18 Million | +139.42% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Imagion Biosystems Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $-193.74 | $0.01 | x |
| 2015-12-31 | $-432.37 | $0.01 | x |
| 2016-12-31 | $0.11 | $0.01 | x |
| 2017-12-31 | $0.04 | $0.01 | x |
| 2018-12-31 | $0.02 | $0.01 | x |
| 2019-12-31 | $0.33 | $0.01 | x |
| 2020-12-31 | $0.69 | $0.01 | x |
| 2021-12-31 | $0.51 | $0.01 | x |
| 2022-12-31 | $0.17 | $0.01 | x |
| 2023-12-31 | $-0.12 | $0.01 | x |
| 2024-12-31 | $-0.05 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Imagion Biosystems Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -77.56%
- • Asset Turnover: 0.95x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-68.06%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | -41159.99% | 0.02x | 0.00x | $-2.12 Million |
| 2015 | 0.00% | -80124.99% | 0.01x | 0.00x | $-3.51 Million |
| 2016 | -8.85% | -8620641.67% | 0.00x | 1.04x | $-2.20 Million |
| 2017 | -112.11% | -38775.26% | 0.00x | 1.10x | $-8.49 Million |
| 2018 | -215.75% | -4359.67% | 0.04x | 1.34x | $-8.73 Million |
| 2019 | -115.44% | -835.46% | 0.08x | 1.64x | $-3.73 Million |
| 2020 | -41.54% | -2607.47% | 0.01x | 1.09x | $-6.66 Million |
| 2021 | -45.28% | -210.98% | 0.20x | 1.06x | $-7.36 Million |
| 2022 | -209.71% | -319.42% | 0.31x | 2.13x | $-10.28 Million |
| 2023 | 0.00% | -250.95% | 1.08x | 0.00x | $-12.10 Million |
| 2024 | 0.00% | -77.56% | 0.95x | 0.00x | $-1.84 Million |
Industry Comparison
This section compares Imagion Biosystems Limited's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Imagion Biosystems Limited (IBXXF) | $-3.87 Million | 0.00% | N/A | $1.74 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |